Pluristem Doses First Patient in Phase I Trial for Treatment of Peripheral Artery Disease

Pluristem Therapeutics Inc. said it dosed the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, in a Phase I clinical trial for the treatment of critical limb ischemia, the end-stage of peripheral artery disease.
RTTNews